The DOI matches its Crossref record; 351 of the 352 references it cites were found in a registry or an index.
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Abstract
A rapid increase in incidence of neurodegenerative disorders has been observed with the aging of the population. Alzheimer's disease (AD) is the most common neurodegenerative disorder among the elderly. It is characterized by memory dysfunction, loss of lexical access, spatial and temporal disorientation and impairment of judgement clinically. Unfortunately, clinical development of drugs for the symptomatic and disease-modifying treatment of AD has resulted in both promise and disappointment. Indeed, a large number of drugs with differing targets and mechanisms of action were investigated with only a few of them being clinically available. The targeted drug delivery to the central nervous system (CNS), for the diagnosis and treatment of neurodegenerative disorders such as AD, is restricted due to the limitations posed by the blood-brain barrier (BBB) as well as due to opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Over the last decade, nanoparticle-mediated drug delivery represents one promising strategy to successfully increase the CNS penetration of several therapeutic moieties. Different nanocarriers are being investigated to treat and diagnose AD by delivering at a constant rate a host of therapeutics over times extending up to days, weeks or even months. This review provides a concise incursion on the current pharmacotherapies for AD besides reviewing and discussing the literature on the different drug molecules that have been successfully encapsulated in nanoparticles (NPs). Some of them have been shown to cross the BBB and have been tested either for diagnosis or treatment of AD. Finally, the route of NPs administration and the future prospects will be discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Resveratrol is the most biologically active compound present in grapes and red wine, and known for its properties of reducing the production of amyloid peptides, in addition to its cytoprotective actions and reduction of cognitive defects [59].”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [59]
In the citing paper
“Resveratrol is the most biologically active compound present in grapes and red wine, and known for its properties of reducing the production of amyloid peptides, in addition to its cytoprotective actions and reduction of cognitive defects [59].”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [59]
In the citing paper
“Resveratrol is the most biologically active compound present in grapes and red wine, and known for its properties of reducing the production of amyloid peptides, in addition to its cytoprotective actions and reduction of cognitive defects [59].”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [59]
Citations
Cites
1 retracted
RETRACTED: α-Lipoic acid exhibits anti-amyloidogenicity for β-amyloid fibrils in vitro
Ono, K., Hirohata, M., & Yamada, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.063 · Cited by 60
RetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Structure-antioxidant activity relationships of flavonoids and phenolic acids
Rice-Evans, C. A., Miller, N. J., & Paganga, G. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(95)02227-9 · Cited by 9,085
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Dietary Intake and Bioavailability of Polyphenols
Scalbert, A., & Williamson, G. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.8.2073s · Cited by 3,658
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
Research works printed but not linked: 7
- Singh, 2008, Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms, J. Agric. Food Chem., 56, 4855, 10.1021/jf0735073 · DOI
- Bieschke, 2010, EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity, Proc. Natl Acad. Sci. USA, 107, 7710, 10.1073/pnas.0910723107 · DOI
- Jang, 2003, Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death, Free Radic. Biol. Med., 34, 1100, 10.1016/S0891-5849(03)00062-5 · DOI
- Sharma, 2002, Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats, Life Sci., 71, 2489, 10.1016/S0024-3205(02)02083-0 · DOI
- Wilson, 2010, Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine, Nanomed. Nanotechnol. Biol. Med., 6, 144, 10.1016/j.nano.2009.04.001 · DOI
- Wilson, 2008, Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease, Brain Res., 1200, 159, 10.1016/j.brainres.2008.01.039 · DOI · Paper page
- Reiter, 2003, Melatonin: clinical relevance, Best Pract. Res. Clin. Endocrinol. Metab., 17, 273, 10.1016/S1521-690X(03)00016-2 · DOI
Cited by
Sorted by citations
Items 201–219 of 219
Potential of nanoparticles as novel therapeutics against Alzheimer’s disease
Ujjwal, R. R., Maharana, S. K., Handa, M., & Krishna, S. T. V. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00015-0
Current Nanodelivery Systems for Imaging and Therapeutics
Kelkar, A. D., Herr, D. J. C., & Ryan, J. G. (2014) · CRC Press eBooks · doi:10.1201/b16957-11
Bălașa, R. (2015) · Romanian Journal of Neurology · doi:10.37897/rjn.2015.4.3
Development of medical polymers for applications in neurological disorders
Espinoza, F., Ide, W., Saldivia, N., & Zelada, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85233-3.00012-4
Role of Nanodiagnostics in Health Sciences
Chitra, A. V., Selvaraj, S., Munusamy, A. P., Kuppanan, N., & Kannan, K. (2022) · Materials horizons · doi:10.1007/978-981-19-2639-6_14
Tiwari, P. K., Geetha, K. M., Shrivastava, S., Kumari, Y., Panik, R. K., Singh, P. K., Kumar, D., & Sahu, P. K. (2023) · Frontiers in clinical drug research. CNS and neurological disorders · doi:10.2174/9789815123319123110006
Novel Theranostics for Parkinson's Disease
Schlichtmann, B. W. (2021) · doi:10.31274/td-20240329-549
Nanofillers on Adhesion Properties of Polymeric Composites
Dave, P. N., & Chaturvedi, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-3516-1_46-1
Unveiling the complexity of Alzheimer's disease: Introduction and its pathophysiology
Shabir, S., & Singh, M. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00012-4
New drugs for Alzheimer’s disease: Aducanumab or Donanemab?
Joodaki, M., Shirazi, M. M., & Hosseini, N. (2024) · Physiology and Pharmacology · doi:10.61186/phypha.28.3.219
Nanofillers on Adhesion Properties of Polymeric Composites
Dave, P. N., & Chaturvedi, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-2407-2_46
Physicochemical properties for potential Alzheimer's disease drugs
Gado, S., Ateş‐Alagöz, Z., & Adejare, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00017-x
Rakotoarisoa, M. (2021) · theses.fr (ABES) · doi:10.70675/7bf6365czfebbz4b3az9400z0a82f6d9364f
Nanotechnology-based Therapeutic Approach in Alzheimer's Disease
Goswami, R., Banerjee, P., Sanyal, S., Basu, B., & Rahaman, M. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010011
Paul, P. S., Borenstein-Katz, A., Shmeit, K., Wille, H., & Kar, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188152
Abdullah, S., Thiab, S. H., Al-Masud, A. A., Alonazi, S. H., AlKhatib, H. S., & Hamadneh, I. (2026) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2026.2736040
Metadata
- Authors
- Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C.
- Affiliations
- Institut National de la Recherche Scientifique (CA)
- Jamia Hamdard (IN)
- Corresponding author
- Ramassamy, Charles
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 152
- Issue
- 2
- Pages
- 208-231
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2040364087
- Cited by
- 219
- References
- 352
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 14 · 2022: 17 · 2021: 14 · 2020: 16 · 2019: 21 · 2018: 18 · 2017: 14 · 2016: 17 · 2015: 16 · 2014: 13 · 2013: 15 · 2012: 13
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- EspaceINRS (National Institute for Scientific Research (Canada)) (submittedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- Alzheimer's disease, nanoparticles, nanocarriers, blood-brain barrier, targeted drug delivery, brain drug delivery, drug encapsulation, nanomedicine, route of administration, neurodegenerative diseases
- MeSH terms
- Alzheimer Disease, Amyloid, Animals, Blood-Brain Barrier, Chelating Agents, Cholinesterase Inhibitors, Flavonoids, Hormones, Humans, Phenols, Vasoactive Intestinal Peptide, Drug Delivery Systems, Nanoparticles, Polyphenols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
